May 6, 2021 By Grow Opportunity staff
Biopharmaceutical company, Avicanna Inc., announced that it has entered into a partnership with Sunnybrook Health Sciences Centre to supply cannabinoid-based products to patients at Odette Cancer Centre pharmacy.
The aim of the partnership, according to Avicanna’s press release, is to establish a gold standard for cannabinoid-based medicine “by providing support and educating and training physicians, pharmacists and patients on the formulary of the RHO Phyto products.” This education initiative will provide support and consultation to both the patients’ physicians and pharmacists to track patient outcomes and promote safe and consistent use of cannabinoid medicines.
“Patients have questions about and want access to plant-based cannabinoids, and that requires healthcare professionals to become knowledgeable about the use of cannabinoids for medical purposes,” said Carlo DeAngelis, pharmacist and researcher at Sunnybrook Hospital’s Odette Cancer Centre. “
Our primary goal is patient safety. This collaboration will help us ensure patients have access to plant-based cannabinoid products of high quality as well as provide education focused on dosing, monitoring of symptoms and effects on concurrent anti-cancer treatments.”
The RHO Phyto products will be supplied to Sunnybrook Hospital through Avicanna’s exclusive medical partnership with Medical Cannabis by Shoppers’ online platform.
Print this page